First Patient Dosed in Ph 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
“Relapsed/refractory T-ALL/LBL remains one of the most difficult-to-treat blood cancers, with 40% of adults relapsing after first-line therapy and facing very limited options,” said Jan Davidson-Moncada, MD, PhD, Imviva Biotech Chief Medical Officer. “The successful dosing of our first U.S. patient represents a meaningful milestone in bringing an innovative off-the-shelf CAR-T therapy to this underserved population. We are well-positioned to advance to Phase 2 in the near future and establish CTD402 as a therapeutic option for patients who urgently need better treatments.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the